Now showing items 1-1 of 1
Retrospective analysis of long-term survival after combination treatment with gemcitabine, oxaliplatin and paclitaxel in patients with refractory or relapsed testicular cancers
(Gulhane Medical School, University of Health Sciences, 2018)
Aims: Testicular tumors are one of the most common malignancies in males, between 15 and 35 years of age. Testicular cancer patients are treated with the combination of gemcitabine, oxaliplatin and paclitaxel (GOP) in ...